

# Frederic Lamoth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2885193/publications.pdf>

Version: 2024-02-01

126  
papers

8,192  
citations

81900

39  
h-index

51608

86  
g-index

133  
all docs

133  
docs citations

133  
times ranked

8627  
citing authors

#	ARTICLE	IF	CITATIONS
1	Invasive aspergillosis in coronavirus disease 2019: a practical approach for clinicians. <i>Current Opinion in Infectious Diseases</i> , 2022, 35, 163-169.	3.1	9
2	Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective. <i>Clinical Infectious Diseases</i> , 2022, 75, 534-544.	5.8	47
3	High False-Positive Rate of (1,3)- $\beta$ -D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies. <i>Clinical Infectious Diseases</i> , 2022, 75, 330-333.	5.8	11
4	Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period. <i>Journal of Infection</i> , 2022, 84, 722-746.	3.3	3
5	Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0006722.	3.2	15
6	<i>Aspergillus tubingensis</i> Endocarditis: A Case Report and Review of the Literature. <i>Mycopathologia</i> , 2022, 187, 249-258.	3.1	5
7	The unresolved issues in the management of mucormycosis. <i>European Journal of Internal Medicine</i> , 2022, 100, 29-30.	2.2	2
8	Distribution of <i>Aspergillus</i> Species and Prevalence of Azole Resistance in Respiratory Samples From Swiss Tertiary Care Hospitals. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab638.	0.9	7
9	Frequency and causes of antifungal treatment changes in allogeneic haematopoietic cell transplant recipients with invasive mould infections. <i>Mycoses</i> , 2022, 65, 199-210.	4.0	2
10	How Yeast Antifungal Resistance Gene Analysis Is Essential to Validate Antifungal Susceptibility Testing Systems. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, .	3.9	3
11	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. <i>Viruses</i> , 2022, 14, 1089.	3.3	9
12	Invasive Aspergillosis Due to <i>Aspergillus</i> Section <i>Usti</i> : A Multicenter Retrospective Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1379-1385.	5.8	28
13	Invasive Pulmonary Aspergillosis Goes Viral Again?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 275-277.	5.6	6
14	Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients. <i>Medical Mycology</i> , 2021, 59, 93-101.	0.7	4
15	Letter on "€(1,3)- $\beta$ -d-Glucan-based empirical antifungal interruption" in suspected invasive candidiasis: a randomized trial". <i>Critical Care</i> , 2021, 25, 55.	5.8	2
16	Insights in the molecular mechanisms of an azole stress adapted laboratory-generated <i>Aspergillus fumigatus</i> strain. <i>Medical Mycology</i> , 2021, 59, 763-772.	0.7	3
17	Guidance on Imaging for Invasive Pulmonary Aspergillosis and Mucormycosis: From the Imaging Working Group for the Revision and Update of the Consensus Definitions of Fungal Disease from the EORTC/MSGERC. <i>Clinical Infectious Diseases</i> , 2021, 72, S79-S88.	5.8	45
18	Assessment of the Role of 1,3- $\beta$ -d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults. <i>Clinical Infectious Diseases</i> , 2021, 72, S102-S108.	5.8	30

#	ARTICLE	IF	CITATIONS
19	Navigating the Uncertainties of COVID-19-associated Aspergillosis: A Comparison With Influenza-associated Aspergillosis. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	50
20	Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. <i>BMC Infectious Diseases</i> , 2021, 21, 296.	2.9	24
21	Limited Index of Clinical Suspicion and Underdiagnosis of Histopathologically Documented Invasive Mold Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab174.	0.9	3
22	Novel <i>ERG11</i> and <i>TAC1b</i> Mutations Associated with Azole Resistance in <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	36
23	Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. <i>Frontiers in Immunology</i> , 2021, 12, 666163.	4.8	27
24	Case Report: SARS-CoV-2 as an unexpected causal agent of isolated febrile hepatitis. <i>F1000Research</i> , 2021, 10, 400.	1.6	1
25	Invasive <i>Hormoglyphiella aspergillata</i> infection in patients with acute myeloid leukemia: Report of two cases successfully treated and review of the literature. <i>Medical Mycology Case Reports</i> , 2021, 32, 68-72.	1.3	5
26	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e049232.	1.9	10
27	COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1376-1378.	6.0	33
28	Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab471.	0.9	15
29	Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital. <i>Mycoses</i> , 2021, 64, 1512-1520.	4.0	11
30	Pancreatitis, hypereosinophilia and bilateral pulmonary infiltrates as presentation of acute Q fever. <i>New Microbes and New Infections</i> , 2021, 43, 100940.	1.6	2
31	Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 17.	3.5	36
32	Assessment of the In Vitro and In Vivo Antifungal Activity of NSC319726 against <i>Candida auris</i> . <i>Microbiology Spectrum</i> , 2021, , e0139521.	3.0	4
33	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020, 71, 1367-1376.	5.8	1,429
34	COVID-19 Pandemics. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e011395.	2.6	3
35	Emerging echinocandin-resistant <i>Candida albicans</i> and <i>glabrata</i> in Switzerland. <i>Infection</i> , 2020, 48, 761-766.	4.7	33
36	Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1706-1708.	6.0	90

#	ARTICLE	IF	CITATIONS
37	Conidiobolus pachyzygosporus invasive pulmonary infection in a patient with acute myeloid leukemia: case report and review of the literature. BMC Infectious Diseases, 2020, 20, 527.	2.9	8
38	Incidentally discovered COVID-19 pneumonia: the role of diagnostic imaging. European Radiology, 2020, 30, 5211-5213.	4.5	15
39	High prevalence of peribronchial focal lesions of airway invasive aspergillosis in hematological cancer patients with prolonged neutropenia. British Journal of Radiology, 2020, 93, 20190693.	2.2	3
40	Risk factors for candidemia: a prospective matched case-control study. Critical Care, 2020, 24, 109.	5.8	92
41	Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis. Open Forum Infectious Diseases, 2020, 7, ofaa075.	0.9	26
42	Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis. Journal of Clinical Microbiology, 2020, 58, .	3.9	19
43	Clinical Relevance and Characteristics of Aspergillus calidoustus and Other Aspergillus Species of Section Usti. Journal of Fungi (Basel, Switzerland), 2020, 6, 84.	3.5	9
44	Validation and clinical application of a multiplex high performance liquid chromatography " tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1157, 122160.	2.3	38
45	Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clinical Microbiology and Infection, 2020, 26, 1178-1182.	6.0	138
46	Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. Journal of Infection, 2020, 81, 131-146.	3.3	62
47	Collapsing glomerulopathy in a COVID-19 patient. Kidney International, 2020, 98, 228-231.	5.2	240
48	Ability of quantitative PCR to discriminate Pneumocystis jirovecii pneumonia from colonization. Journal of Medical Microbiology, 2020, 69, 705-711.	1.8	26
49	Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult. Swiss Medical Weekly, 2020, 150, w20387.	1.6	27
50	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. Journal of Antimicrobial Chemotherapy, 2019, 74, 532-533.	3.0	3
51	Successful treatment with daptomycin and ceftaroline of MDR Staphylococcus aureus native valve endocarditis: a case report. Journal of Antimicrobial Chemotherapy, 2019, 74, 2626-2630.	3.0	10
52	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
53	Therapeutic Challenges of Non- <i>Aspergillus</i> Invasive Mold Infections in Immunosuppressed Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	68
54	Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	82

#	ARTICLE	IF	CITATIONS
55	Link between Heat Shock Protein 90 and the Mitochondrial Respiratory Chain in the Caspofungin Stress Response of <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
56	Diagnosis and treatment of invasive fungal infections: looking ahead. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, ii27-ii37.	3.0	66
57	Diagnostic approach to encephalitis and meningoencephalitis in adult returning travellers. <i>Clinical Microbiology and Infection</i> , 2019, 25, 415-421.	6.0	10
58	Isavuconazole brain penetration in cerebral aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1751-1753.	3.0	30
59	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUN</sc>gal infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	4.0	53
60	Role of bi-weekly serum galactomannan screening for the diagnosis of invasive aspergillosis in haematological cancer patients. <i>Mycoses</i> , 2018, 61, 350-354.	4.0	7
61	Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study. <i>Journal of Infection</i> , 2018, 76, 489-495.	3.3	13
62	The <i>Candida auris</i> Alert: Facts and Perspectives. <i>Journal of Infectious Diseases</i> , 2018, 217, 516-520.	4.0	66
63	Changes in the epidemiological landscape of invasive candidiasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, i4-i13.	3.0	349
64	Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3413-3422.	3.0	40
65	Efficacy of Antifungal Monotherapies and Combinations against <i>Aspergillus calidoustus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
66	Let's add invasive aspergillosis to the list of influenza complications. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 733-735.	10.7	19
67	Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant <i>Candida albicans</i> and <i>Candida glabrata</i> : a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS). <i>Clinical Microbiology and Infection</i> , 2018, 24, 1214.e1-1214.e4.	6.0	20
68	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. <i>Haematologica</i> , 2018, 103, e527-e530.	3.5	26
69	First case of <i>Candida auris</i> in Switzerland: discussion about preventive strategies. <i>Swiss Medical Weekly</i> , 2018, 148, w14622.	1.6	28
70	Early diagnosis of invasive mould infections and disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, i19-i28.	3.0	87
71	Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1619-1621.	5.8	107
72	Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia. <i>Intensive Care Medicine</i> , 2017, 43, 935-939.	8.2	5

#	ARTICLE	IF	CITATIONS
73	Editorial: Advances in <i>Aspergillus fumigatus</i> Pathobiology. <i>Frontiers in Microbiology</i> , 2016, 7, 43.	3.5	5
74	<i>Aspergillus fumigatus</i> -Related Species in Clinical Practice. <i>Frontiers in Microbiology</i> , 2016, 7, 683.	3.5	125
75	Galactomannan and 1,3- $\beta$ -D-Glucan Testing for the Diagnosis of Invasive Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2016, 2, 22.	3.5	55
76	Role of Antifungal Susceptibility Testing in Non- <i>Aspergillus</i> Invasive Mold Infections. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1638-1640.	3.9	28
77	Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4727-4733.	3.2	25
78	Potential Microbiological Effects of Higher Dosing of Echinocandins. <i>Clinical Infectious Diseases</i> , 2015, 61, S669-S677.	5.8	53
79	Antifungal activity of compounds targeting the Hsp90-calcineurin pathway against various mould species. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1408-1411.	3.0	37
80	Comparing Etest and Broth Microdilution for Antifungal Susceptibility Testing of the Most-Relevant Pathogenic Molds. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3176-3181.	3.9	42
81	Identification and mutational analyses of phosphorylation sites of the calcineurin-binding protein CbpA and the identification of domains required for calcineurin binding in <i>Aspergillus fumigatus</i> . <i>Frontiers in Microbiology</i> , 2015, 6, 175.	3.5	14
82	The <i>Aspergillus fumigatus</i> septins play pleiotropic roles in septation, conidiation, and cell wall stress, but are dispensable for virulence. <i>Fungal Genetics and Biology</i> , 2015, 81, 41-51.	2.1	35
83	Calcium-Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4946-4955.	3.2	39
84	Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis. <i>Frontiers in Microbiology</i> , 2015, 6, 96.	3.5	61
85	Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non- <i>Aspergillus</i> Mold Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4308-4311.	3.2	78
86	Waddlia: An emerging pathogen and a model organism to study the biology of chlamydiae. <i>Microbes and Infection</i> , 2015, 17, 732-737.	1.9	10
87	Heat Shock Protein 90 (Hsp90) in Fungal Growth and Pathogenesis. <i>Current Fungal Infection Reports</i> , 2014, 8, 296-301.	2.6	8
88	Calcineurin-Mediated Regulation of Hyphal Growth, Septation, and Virulence in <i>Aspergillus fumigatus</i> . <i>Mycopathologia</i> , 2014, 178, 341-348.	3.1	35
89	Transcriptional Activation of Heat Shock Protein 90 Mediated Via a Proximal Promoter Region as Trigger of Caspofungin Resistance in <i>Aspergillus fumigatus</i> . <i>Journal of Infectious Diseases</i> , 2014, 209, 473-481.	4.0	57
90	Identification of a Key Lysine Residue in Heat Shock Protein 90 Required for Azole and Echinocandin Resistance in <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1889-1896.	3.2	68

#	ARTICLE	IF	CITATIONS
91	Heat shock protein 90 (Hsp90): A novel antifungal target against <i>Aspergillus fumigatus</i> . <i>Critical Reviews in Microbiology</i> , 2014, 42, 1-12.	6.1	52
92	Nonmolecular Methods for the Diagnosis of Respiratory Fungal Infections. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 315-336.	1.4	37
93	Calcineurin as a multifunctional regulator: Unraveling novel functions in fungal stress responses, hyphal growth, drug resistance, and pathogenesis. <i>Fungal Biology Reviews</i> , 2014, 28, 56-69.	4.7	113
94	Polymorphisms in Tumor Necrosis Factor- $\beta$ Increase Susceptibility to Intra-Abdominal <i>Candida</i> Infection in High-Risk Surgical ICU Patients*. <i>Critical Care Medicine</i> , 2014, 42, e304-e308.	0.9	17
95	$\beta$ -Glucan Antigenemia Anticipates Diagnosis of Blood Culture "Negative Intraabdominal Candidiasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1100-1109.	5.6	183
96	Phosphorylation of Calcineurin at a Novel Serine-Proline Rich Region Orchestrates Hyphal Growth and Virulence in <i>Aspergillus fumigatus</i> . <i>PLoS Pathogens</i> , 2013, 9, e1003564.	4.7	60
97	In Vitro Activity of Calcineurin and Heat Shock Protein 90 Inhibitors against <i>Aspergillus fumigatus</i> Azole- and Echinocandin-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1035-1039.	3.2	74
98	$\beta$ -Glucan Antigenemia Assay for the Diagnosis of Invasive Fungal Infections in Patients With Hematological Malignancies: A Systematic Review and Meta-Analysis of Cohort Studies From the Third European Conference on Infections in Leukemia (ECIL-3). <i>Clinical Infectious Diseases</i> , 2012, 54, 633-643.	5.8	260
99	Heat Shock Protein 90 Is Required for Conidiation and Cell Wall Integrity in <i>Aspergillus fumigatus</i> . <i>Eukaryotic Cell</i> , 2012, 11, 1324-1332.	3.4	122
100	ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. <i>Bone Marrow Transplantation</i> , 2012, 47, 846-854.	2.4	222
101	Immunogenetics of invasive aspergillosis. <i>Medical Mycology</i> , 2011, 49, S125-S136.	0.7	17
102	European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3 "2009 Update. <i>Bone Marrow Transplantation</i> , 2011, 46, 709-718.	2.4	402
103	Monitoring Procalcitonin in Febrile Neutropenia: What Is Its Utility for Initial Diagnosis of Infection and Reassessment in Persistent Fever?. <i>PLoS ONE</i> , 2011, 6, e18886.	2.5	39
104	Parachlamydia and Rhabdochlamydia: Emerging Agents of Community-Acquired Respiratory Infections in Children. <i>Clinical Infectious Diseases</i> , 2011, 53, 500-501.	5.8	26
105	Comparison of hospital-wide and unit-specific cumulative antibiograms in hospital- and community-acquired infection. <i>Infection</i> , 2010, 38, 249-253.	4.7	16
106	Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. <i>BMC Infectious Diseases</i> , 2010, 10, 2.	2.9	21
107	Amoebal pathogens as emerging causal agents of pneumonia. <i>FEMS Microbiology Reviews</i> , 2010, 34, 260-280.	8.6	97
108	Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. <i>Clinical Transplantation</i> , 2010, 24, 794-800.	1.6	14

#	ARTICLE	IF	CITATIONS
109	Disseminated <i>Rhizopus microsporus</i> infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection. <i>Transplant Infectious Disease</i> , 2010, 12, 269-272.	1.7	17
110	Multiplex Blood PCR in Combination with Blood Cultures for Improvement of Microbiological Documentation of Infection in Febrile Neutropenia. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3510-3516.	3.9	101
111	Ultra-Performance Liquid Chromatography Mass Spectrometry and Sensitive Bioassay Methods for Quantification of Posaconazole Plasma Concentrations after Oral Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5074-5081.	3.2	21
112	The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. <i>Critical Care</i> , 2010, 14, R222.	5.8	250
113	High Cefepime Plasma Concentrations and Neurological Toxicity in Febrile Neutropenic Patients with Mild Impairment of Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4360-4367.	3.2	147
114	Fastidious intracellular bacteria as causal agents of community-acquired pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 775-790.	4.4	35
115	Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 785-787.	3.2	37
116	Population Pharmacokinetics of Ganciclovir in Solid-Organ Transplant Recipients Receiving Oral Valganciclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3017-3023.	3.2	43
117	<i>Parachlamydia</i> and <i>Rhobdochlamydia</i> in Premature Neonates. <i>Emerging Infectious Diseases</i> , 2009, 15, 2072-2075.	4.3	32
118	Imipenem underdosing as a cause of persistent neutropenic fever?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 665-667.	3.0	6
119	On track to limit antifungal overuse!. <i>Intensive Care Medicine</i> , 2009, 35, 582-584.	8.2	8
120	High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 386-388.	2.5	15
121	Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. <i>Clinical Transplantation</i> , 2008, 22, 245-249.	1.6	30
122	Case Report: Human herpesvirus 6 reactivation associated with colitis in a lung transplant recipient. <i>Journal of Medical Virology</i> , 2008, 80, 1804-1807.	5.0	22
123	What Is the Impact of Late-Onset Cytomegalovirus Disease After Valganciclovir Prophylaxis in Kidney Transplantation?. <i>Transplantation</i> , 2008, 86, 1323-1324.	1.0	7
124	Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature. <i>Antiviral Therapy</i> , 2008, 13, 1001-9.	1.0	7
125	Low-dose Cidofovir for the Treatment of Polyomavirus-Associated Nephropathy: Two Case Reports and Review of the Literature. <i>Antiviral Therapy</i> , 2008, 13, 1001-1009.	1.0	20
126	Blood samples drawn for culture as a surrogate marker for case-mix adjustment of hospital antibiotic use. <i>Clinical Microbiology and Infection</i> , 2007, 13, 454-456.	6.0	3